Mike everyone. you, Thank and hello
and The third quarter positive been DURECT. second early have very for quarter
We completion dosed all in first data continue impressive to in announcement of patients XX our the announcement milligram AH consistent with patients response report in preliminary the our fronts was of and data program XX dose with on XXX DUR-XXX the the dose milligram this those With year. from severe patients that the from hepatitis all advance alcoholic initiation remaining flagship the AH response track cohort DUR-XXX three DUR-XXX with the XX --with with patients. those clinical trials patients the cohorts the XX with milligram first on of and to severe
XX.We December a $XX a of our substantially submitted and and we a with response signed goal letter We million. to also complete license of free response addition Gilead have POSIMIR sheet received user with the major agreement the balance date strengthened
-class atopic the important acute as alcohol hepatitis psoriasis survival. and injuries on deal Gilead and plays regulatory is such broad homeostasis, kidney functions the acute POSIMIR the such It are positive small primary a and chronic in disorders of compound lipid applicability liver program inflammation diseases dermatitis. remains skin and that injury and such on as may DUR-XXX role and and inflammatory as have DURECT’s organ NASH achievements, cell naturally an DUR-XXX. molecule vital filing While epigenetic significant focus lead our first-in regular occurring
steatohepatitis non-alcoholic indications; initial developing by our by injection, are oral program. and topical hepatitis currently route. dosing in three with will by We alcoholic I DUR-XXX hepatitis, begin or alcoholic NASH AH psoriasis or
study initial and each dose Xaopen-label XX patients subsequent escalation following by severe results U.S. AH meld safety dose a Phase with dose conducting the to review the their multicenter clinical that XXX moderate testing as Escalation level by approval and score. dose DUR-XXX. milligram prior it’s committee We're requires pharmacokinetic the and study determined from includes XX, of Its escalation doses level. a of
The The study safety, for and including is chemistry four liver assessment four of per patients moderate the target study patients pharmacokinetics objectives pharmacodynamics biomarkers. of number signals, and severe include and dose.
AH AH we moderate represents announced May XX% for Phase in key and AH XX% mortality the with therapies preliminary key a XX significant together severe the rate medical approved some leaders for our from In treated for data patients our -- no and first around with opinion study. DUR-XXX Xa is with need unmet patients.
serum were Lille, patients AH MELD from as The a and from these Lille Bilirubin The first bilirubin patients lower statistically and MELD and data historical reductions levels impressive. XX scores baseline, demonstrated significantly compared scores control. to from statistically significant these data
was the In severity by influenced addition,DUR-XXX disease. well-tolerated not pharmacokinetic were the of parameters and
and the in above have practice the only AH the with survival month a an treatment. days six Lille seven X.XX prognosis determine with AH are below of Lille XX% those X.XX used help after better scores lower Patients XX% The to clinical Lille is for patient. score, have a six patients Lille of scores month the survival rate. the score prognosis rate
care for treated treated in historical University for nine return patients of In of from with corticosteroid the our group with cohort control median a the visit Millville X.XX patients among and XXX the was the study that to Lille was who X.XX and score range Lille AH a supportive either with care day score median seven or X.XX were supportive their X.XX.The preliminary data of XX
the The X.XXX that rank Lille the from with were scores of patients test. than Louisville Wilcox statistically P value in lower significantly the by patients sum DUR-XXX
serum bilirubin scores in level alcoholic the major One hepatitis of is well Lille other as of as patients. components the score our prognostic
of reductions preliminary XX at at in In bilirubin statistically patients The the in and of Louisville compared at our of the XX% control patients. at of DUR-XXX treated there XX% and significant In the compared were AH seven bilirubin seven from patients contrast care the standard day significant. serum in DUR-XXX day in as was day seven the baseline treated XX both day at XX% seven patients day or day at University University and were data total Louisville total reduction as in group day day XX. no reductions statistically to median to XX to either X%
Patients of are XX of scoring score patients AH. model XX with having classified The moderate disease to MELD another is system AH severity to AH assess to with as end-stage scores XX patients. of MELD the or used severe and liver and XX prognosis
the prognosis is score AH better As Lille lower scores for patient. the the the MELD
significant. a XX control reduction X% day there and was preliminary day X% X% median treated MELD the seven at DUR-XXX our significant. day on the XX was reduction the on of In was the patients UL baseline at In the from significantly XX prior day of reduction data statistically – data for latter which statistically seven was treatment neither patients – day is that to XX% and prior a the
severe patients the initial milligram described data XX June, the data from In consistent patients. XX severe announced I with in XX the was dosing from and preliminary the cohort milligram we completed we the preliminary just
patients the present the at milligram hope We from meeting enrolling AH We XX in patient in and moderate at cohort milligram currently XXX level this cohort. the data Boston this are trial November. AASLD severe to
patients in Craig Louisville from his efforts of In our an supporting the the University at injury liver initiate associated is parallel damage. are is progressive of injury in study from AH encompasses Dr. with it estimated The and severe AH we a occur McClain somewhere of drinkers. ongoing life-threatening NIH heavy XX% University. liver funded AH spectrum DUR-XXX trial to with intake syndrome that to prevalence alcohol of inflammatory ranges to to is long-term heavy XX% between mild a AH of
to According in cost the $XX,XXX hospitalizations the of States to of alcoholic article hepatitis Gastroenterology per were in Journal liver hospitalization an patient in XXX,XXX $XXX,XXX. United resulting nearly exceeds our XXXX the of and related over transplant there Clinical in cost
In summary, serum and patients results dosed Lille and data consistent bilirubin demonstrate from with medical first low XX The XX our preliminary Results patients. XX near-term significant XX% from to the need rates XX%. from reductions unmet scores. AH for milligram patients severe first DUR-XXX with the AH of represents were MELD a the positive mortality clinical AH
is We which are enrolling the in of the XXX patients. milligram the final cohort severe AH four of trial group
to trial We expect we at Xb approval. FDA trial may would an believe market. been the data from coming lifesaving completed, path to to the this that DUR-XXX in be has next Boston present could accelerated for path this step initiated the AASLD be We meet we discuss eligible the trial age therefore meeting will the year. in the November. Once to And the with potential be has and next which be to Phase patients hope
study, a day patients days. XXX evaluating of to for milligrams being I’ll now XXX a NASH signals In in conducted pharmacokinetics to we United patients fibrosis. or an day. with to is once NASH In doses twice of Ib XX nonalcoholic move evaluate this at or activity biological administered or the in March, study our Phase milligrams being in XX X we're steatohepatitis label enrolling safety began stage the orally milligrams DUR-XXX X XXX a XXX open clinical program. randomize of States and consecutive
we approximately and being lipids, maintain data fat. liver the as from total The There endpoints with will chemistry group a patients per is examples key MRI-PDFF well of XX study patients imaging in includes of our year. this half expectation pharmacokinetics, inflammatory clinical and about this measuring initial be liver announce the for to biomarkers study and second in dose this trial. bilirubin, enzymes, XX will be from CK-XX cytokines for We safety
our psoriasis DUR-XXX. program Now to for
approximately for evaluable applying DUR-XXX and serves arm. are patients the one to in trial mild conducting Phase X vehicle-control, patients States. for own once the applied additional is planned other are which clinical daily on United in an arm double-blind, the We to followed treatment randomized moderate plaque trial is the enrolled The X-week. multiple be obtain their weeks plaque to to in Each on being patient XX sites psoriasis. XX a vehicle patients. are DUR-XXX control, clinical plaque a period, similar as to with proof-of-concept patients at topically conducted After IIa
local expectation DUR-XXX-treated enrolling plaques. primary in this began topline maintain the data endpoint our the patients year. of change in in that The plaques efficacy psoriasis this second baseline and in to study scores announce as half March from the compared to is We vehicle-treated in from
of replace painful. the in X.X about estimated an X% Federation days have the psoriasis. million disease Psoriasis Americans. is to people an skin with irritation itchiness according inflammatory causes be Psoriasis International some world's Psoriasis rather that immune-mediated affects Psoriasis form the and And and weeks. condition to or skin cells million population, of Associations, body of may XXX than nearly causes
approved of mainstay of treatment. There can treated topical is symptoms. treatment the the with psoriasis agents with no as be patients have which ease Approximately And cure, remain can XX% localized currently therapies. disease, result topical psoriasis but
Now XXX signed a deal development recent to the million where he Last receive and two announcements, to milestones received license upfront B hepatitis the announced We eligible this HIV deal. from an important and our being first are commercialization additional had Gilead. drug we Monday, recently we with product. Gilead $XXX most in million fee delivery – that
long-acting makes Gilead the feasibility HIV pills compliance multiple a take this injectable A work This lot of multiple problem. amount with can anti-HIV of deal Patients combination a formulations. like product on become of substantial times a sense. and day with typically a long-acting injectable was
a days prescribed your of about times for were Just you job think antibiotic multiple do time how number an day that remembering to be you last to good the in a meds. taken
constant to blood dosing resistance to to the of disease. leased Not potential frequent a the and mention reminder levels Noncompliance for develop. inconsistent is
frequently with of complication issue day of is dosing. meds daily for blood such or to complicated of as and Another other that the can a pressure lead interactions medications dosing anti-HIV potential statin
market as of HIV to their patient long-acting release extended reminder required shifting as potential an the products well to a the injectable treatment may taking allow medication. to in disease other for become free injectable from greater available. of the flexibility when treat benefits significant Having would portion they These daily HIV lead
on as with this two feasibility We've about a years Gilead together been working project. program for
a and progress on HIV development advance to to are based into Gilead hepatitis they virus. that is this a our We in effort B chose products formal delighted leader together program. global treat
help and In fact we're patients been proud be to $XX.X Gilead them years in year. this directed to sold last treat able to billion in They products treating many HIV for HIV mission. have
HIV the technology. of commercialize a injectable an million Gilead potential and granted SABER investigational with utilizing for DURECT develop terms to this Gilead regulatory worldwide on $XX payment we specific Gilead million an Under controlling long-acting $XX and sales-based to to XX additional made upfront our exclusive the programs. agreement product the tiered additional the sales directing up milestones in product in will collaborate on million royalties milestones. development development funding rights and and activities with development Gilead An
SABER an product. receives HIV hepatitis as well additional in to also tiered the to B. as and directed platform upfront HIV license products with an exclusive access DURECT additional for sales-based Gilead B exclusive and each regulatory SABER-based royalties and million XXX development receive will new milestones option to for hepatitis
designed products. provide is technology Sucrose a injectable Our Extended which for that technology is is Isobutyrate Acetate release sustained long-acting SABER Release to patented
SABER of POSIMIR is a the basis our As product. technology reminder also
that, relief for depot directly by designed postoperative to to any been POSIMIR that our FDA surgical the to in now surgery. It three days I’ll the up United approved SABER POSIMIR. the update an pain utilizes bupivacaine after technology. of indication. marketing POSIMIR Speaking States for for to not be on is site product patented investigational is is administered deliver
In to response that our June, we response we announced POSIMIR had submitted the letter. complete
goal later a the X submission file as to fee December this announced resubmission NDA of of a fee XX on year. year. FDA user date December agreed to Just XX, goal and find XX had XX date our a we Class NDA XXXX assigned complete this and , resubmission user days July
The about efficacy. CRL We on to correspondence Lee to to response evidence the the then approval efforts Simon address of raised POSIMIR to the seeks and in Dr. CRL to existing CRL. our including intended our raised submission safety and and address POSIMIR commissioned submit based the FDA the issues of evaluate advisors adequacy believe is issues we to the and package the FDA what lead in and the adequate is the
Simon Dr. anti-inflammatory of SDG and LLC the to as who advisory division served XXXX and principal is now and is from a scientists FDA Director physician a products research and firm. FDA's the ophthalmologic drug XXXX at analgesic
patients adequate and undergoing repair two hernia clinical or decompression in reminder, a As surgery. in inguinal shoulder and well-controlled trial conducted subacromial
X,XXX as postoperative and XX to trials XXX trials company require support POSIMIR control pain in and demonstrated all significant placebo. following groups. period our remainder POSIMIR decrease pivotal clinical be which the compared the believe POSIMIR the are considered in to to a hour In pain received trials. We involving space POSIMIR of opioids the over in the has of consumed these with over and completed over surgery efficacy safety clinical X whom program patients and the XX
the as included extensive believe current this PERSIST the safety such believe data PERSIST the address the additional analyses We response sufficiently a data FDA's in NDA from to The – We safety is includes trial issues and sufficient complete are now database. that submission were trial sufficient FDA an new raised that letter. not included XXX with sized the adds patients. data there that original in
remains POSIMIR pain Regarding postoperative the The approximately moderate-to-extreme patients for opportunity pain indicating significant a after of insufficient study surgery. is that problem. experienced XX% control
New that non-opioid if approved. could much-needed are the believe an POSIMIR be pain products setting and postoperative pain important contributor in we
a capabilities to with the partner to space. in hospital file Upon we would plan approval, license excellent commercial
believe garner POSIMIR, returns. significant of the Given could potential economic we value the deal
in quarterly antipsychotic. XX might we which of this by was injectable Next generated to and We’ve sales long-acting of on also product in for has so year force field February with payment with received single-digit $XX.X in in U.S. launched far. the for previously and and the a received. under net milestone percentage one payments a Indivior based agreement end PERSERIS at PERSERIS, payment early is Indivior is Indivior earn-out launch products a receiving expect earn-out million The our upfront of representatives as its modest as addition so
the by some metrics launch encouraged of and by statements early Indivior. We’re
their established managed antipsychotics. is and injectable healthcare expect $XXX line already they million further they achieved their with year. $XXX and announced positive which expectations. per feedback over at reach to are receiving long-acting stated the they've is Indivior of example For previously parity nationally care that patient peak between XX% the coverage revenue in that with annual revenue provider have million to They that
the In summary, to are compared Lille scores preliminary with IIa AASLD Phase maybe and November. we data define completing this trial the state. complete, meet the path We look plan AH and XXX disease at controls lifesaving historical cohort in the impressive. FDA the data most from patient milligrams AH is the in The DUR-XXX trial is meeting presenting to potentially approval. Once to to compelling severe when trial forward drug the to
advisers The strong NASH for We track by topical and end trial support year. investigators encouragement remains by data end yield are The proof-of-concept DUR-XXX psoriasis from on topline year. for and day of data DUR-XXX our have IIa trial the thankful of track expert this to product. clinical the to this the initial Phase the remains on in XX
of excited hepatitis prospect look partnership. products HIV B. well working to and Gilead are injectable the additional and HIV our the a investigational We We December commercial as forward XX to with long-acting be them as on and SABER POSIMIR to their DURECT of with potential NDA product approval potential
to be Indivior's to well. seems Lastly launch going POSIMIR
like take questions we’d any you that, to With might have.
